Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

BIOkey beats profit target, misses revenue forecast and stock falls sharply

BIOkey reported an adjusted loss of $0.56 per share for Q2/2026, beating expectations, while revenue of $1.92 million missed the consensus of $2.2 million. Gross margins and licensing income rose significantly, and net loss narrowed 51% year over year, but a delayed large order and a warrant financing weighed on the market reaction. The stock fell about 12%; management expects profitability in H2/2026 and sees growth potential in Passkey:YOU, PortalGuard 7.0 and in EMEA/Middle East. » More on de.investing.com
BIO key increases revenue by 13%; net loss halved

BIO key reported Q2 revenue of USD 1.9 million (up 13%) and a halved net loss of USD 577,000. License revenues rose 53% to USD 1.2 million, while hardware sales fell 19%; expected hardware sales of about USD 800,000 were pushed into H2 2026. Gross margin improved to 87%; cash balance increased to over USD 4.5 million following the exercise of warrants. The company announced several customer contracts (including Saudi Arabia, Portugal, Jordan) and completed a 1:10 reverse stock split, restoring NASDAQ listing requirements. » More on de.investing.com
BIO-key receives reprimand from Nasdaq over late 10-Q filing

BIO-key received a reprimand from Nasdaq for noncompliance with Rule 5250(c)(1) after the quarterly report (Form 10-Q) for the period ended March 31, 2026 was not filed with the SEC on time. The Nasdaq Hearing Panel will take the violation into account when deciding on the company’s continued listing on the Nasdaq Capital Market. The stock has fallen 41% over the past six months and is currently trading at $4.10 with a market capitalization of about $4.45 million; InvestingPro rates the financial position as “WEAK” with a score of 1.67, but sees possible undervaluation. » More on de.investing.com

Financials

In the last quarter, BIO-Key International had revenue of €1.68m and net profit of -€505.44k

(EUR)	June 2026	YoY
Revenue	1.68m	16.85%
Gross profit	1.47m	40.25%
Net profit	-505.44k	48.97%
EBITDA	-380.67k	56.91%

Fundamentals

Metric	Value
Market capitalization	€3.39m
Number of shares	1.44m
52-week high/low	€12.38 - €1.39
Dividends	No
Beta	0.40
P/E ratio	-0.65
PEG ratio	0.00
P/B ratio	0.63
P/S ratio	0.55

Company profile

BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premises SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions that develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.